Atrium Therapeutics Inc RNA

US Biotechnology

$8.20 ▼ -2.15% ($-0.18)

⬇️ Below Yest. Low 🔥 High Short Interest 📅 Earnings This Week

Open $8.30

Prev Close $8.38

Day Range $8.11 – $8.41

52W Range $7.49 – $73.06

Market Cap $186.67M

Beta 1.20

EPS (TTM) $-5.04

📋 Company Profile

Industry	Biotechnology
Country	US
Exchange	NASDAQ NMS - GLOBAL MARKET
Currency	USD
IPO Date	2026-02-27
Shares Out.	22,280,000
Phone	13026587581
Employees	391
Website	aviditybiosciences.com ↗
Revenue	$3.0M
Gross Profit	$3.0M
Net Income	-$20.2M
Total Assets	$280.5M
Total Liabilities	$65.9M
Equity	$214.6M

About Atrium Therapeutics Inc

Atrium Therapeutics Inc is a biopharmaceutical firm focused on developing RNA-based therapeutics for cardiac conditions, including cardiomyopathies. Its platform technology is designed to enable targeted delivery of RNA therapeutics to heart tissue by combining ligand-based targeting approaches with oligonucleotide-based therapies. The company's development pipeline includes programs targeting genetically associated forms of cardiomyopathy, specifically involving the PRKAG2 and PLN genes.

Atrium Therapeutics Inc is a publicly traded company under the ticker symbol RNA on the NASDAQ NMS - GLOBAL MARKET, operating in the Biotechnology industry. Quotes and metrics shown here are sourced from public market data and refreshed regularly.